Results 171 to 180 of about 8,310 (238)

When should RWE studies be prioritized for reimbursement? Insights from the Canadian perspective. [PDF]

Int J Technol Assess Health Care
Boss J, Shulak L, Rao T, Tam C, Sullivan SM.   +4 more
europepmc   +1 more source

R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 24. [PDF]

J Comp Eff Res
Arora P, Ramagopalan SV.
europepmc   +1 more source

Hyperkalemia management in heart failure and chronic kidney disease: a Spanish cost-effectiveness analysis of patiromer informed by the integrated DIAMOND trial and real-world evidence. [PDF]

BMC Health Serv Res
Bayes-Genis A, Butler J, Stawowczyk E, Turner M, Lewis RD, Lloyd IT, Ramirez de Arellano A.   +6 more
europepmc   +1 more source

Editorial: Advancement of RWD/RWE utilization for enhancing drug development and benefit/risk assessment. [PDF]

Front Pharmacol
Uyama Y, Bérard A, Chan KA.
europepmc   +1 more source

Clinical Evaluation of Allergen Immunotherapy for Allergic Rhinitis. [PDF]

Vaccines (Basel)
Catamerò F, Bragato MC, Lozano MA, Canonica GW, Hernández DB, Escribese MM, Heffler E, Pfaar O, Sahiner U, Paoletti G, Giovannini M.   +10 more
europepmc   +1 more source

CAR in R/R FL: is real-world efficacy meeting expectations? [PDF]

Blood Adv
Bourbon E, Bachy E.
europepmc   +1 more source

Advancing health technology assessment in Taiwan: over 15 years of evidence-based reform, innovation, and patient partnership. [PDF]

Int J Technol Assess Health Care
Huang LY, Lin SY, Liu MH.
europepmc   +1 more source

Bridging evidence worlds: policy and practice pathways for integrating clinical trials and real-world data in drug development and HTA. [PDF]

Front Pharmacol
Sagkriotis A.
europepmc   +1 more source

Supporting complex mental health care and services research today and beyond: a mini-review of real-world evidence strategies and informed approaches. [PDF]

Front Health Serv
Hendricks-Sturrup RM, Gaspar FW.
europepmc   +1 more source